SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Photo of Basel, Switzerland, and Rhine river
Business
Basel Life Sciences Scene Embraces International Companies, Startups
The Basel area is home to over 800 life sciences companies, including Novartis and Roche, according to nonprofit Basel Area Business & Innovation. The nonprofit’s CEO and a BeOne Medicines executive discuss the location’s evolution, advantages and future.
November 6, 2025
 · 
6 min read
 · 
Angela Gabriel
FDA
Webinar: FDA in 2025: Navigating an Uncertain Regulatory Future
The FDA is undergoing a major transformation in its drug approval processes, regulatory oversight and transparency initiatives. This webinar explores the implications of these reforms and what they mean for innovation, compliance and strategy in the biopharma industry.
November 5, 2025
 · 
1 min read
 · 
Jef Akst
Aggressive obstacle from the boss. Concept illustration. Vector illustration
Obesity
Is Metsera Worth the Fuss?
Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: Is the obesity biotech really worth this much effort?
November 5, 2025
 · 
4 min read
 · 
Annalee Armstrong
FDA Headquarters_Grandbrothers/Adobe Stock
Rare diseases
FDA Overruled Reviewers in Approving Stealth’s Barth Syndrome Treatment
According to reporting from Reuters, reviewers at the agency pointed to an inability to differentiate from placebo to justify rejecting the drug, but an FDA office director approved the drug anyway.
November 5, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Business concept illustration of a businessman being pointed by giant fingers
Earnings
Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama
Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company reported third-quarter earnings. A rough quarter underscored the stakes for the Danish pharma.
November 5, 2025
 · 
5 min read
 · 
Annalee Armstrong
Podcast
Pfizer and Novo Battle Over Metsera, Tidmarsh Fights FDA Exit, UniQure and Sarepta Face Setbacks
Pfizer and Novo Nordisk continue to fight for ownership of obesity startup Metsera; CDER Director George Tidmarsh leaves his position amid an ongoing probe into his “personal conduct”; FDA reverses course on approval requirements for uniQure’s Huntington’s gene therapy; Sarepta’s exon-skipping Duchenne muscular dystrophy drugs fail confirmatory study.
November 5, 2025
 · 
1 min read
 · 
Heather McKenzie
Poster sketch image artwork photo collage of body language finger showing gesture symbol thumb down dislike dissatisfied minus no opinion.
Rare diseases
Biohaven Cuts R&D Spending by 60% After FDA Rejection of Drug for Rare Neurodegenerative Disease
Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.
November 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Conceptual business illustration of upcoming business problem metaphor with falling domino and businessman silhouette. Minimalistic vector eps 10 illustration
Preclinical
Arena BioWorks Folds Less Than Two Years After Launch, Blames ‘Policy Uncertainty’
Arena launched with $500 million in early 2024 to fund basic biological research, from which it planned to spin out dedicated companies to focus on drug development.
November 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Missed Target
Rare diseases
Harmony Freezes Cannabidiol Gel After Phase III Miss in Fragile X Syndrome
Harmony Biosciences has paused a mid-stage trial of ZYN002 in 22q11.2 deletion syndrome after the THC-free cannabinoid drug failed to significantly improve social avoidance in a late-stage study in fragile X Syndrome.
November 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS